Recent Developments in Sickle Cell Disease Treatments Globally, the treatment for SCD continues to evolve, albeit the challenges. Voxelotor, a drug marketed as Oxbryta by Pfizer, was hailed as a ...

Oxbryta (voxelotor) is a brand-name drug that’s prescribed for sickle cell disease in adults and certain children. As with other drugs, Oxbryta can cause side effects, such as headache ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood ... the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon ...

What is Oxbryta for sickle cell disease? Oxbryta (voxelotor), which is now withdrawn from the market due to safety concerns, was an oral small molecule conditionally approved in the U.S. for children ...

Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.